Associations - CD3 agonist

No biomarker	Acute Lymphocytic Leukemia	No biomarker	Acute Lymphocytic Leukemia	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1
No biomarker	B Acute Lymphoblastic Leukemia	No biomarker	B Acute Lymphoblastic Leukemia	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1
CD19 positive	Acute Lymphocytic Leukemia	CD19 positive	Acute Lymphocytic Leukemia	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1
No biomarker	Childhood B Acute Lymphoblastic Leukemia	No biomarker	Childhood B Acute Lymphoblastic Leukemia	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1
CD19 positive	B Acute Lymphoblastic Leukemia	CD19 positive	B Acute Lymphoblastic Leukemia	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	teclistamab-cqyv Sensitive: A1 - Approval teclistamab-cqyv Sensitive : A1	teclistamab-cqyv Sensitive: A1 - Approval teclistamab-cqyv Sensitive : A1
HLA-A*02:01	Uveal Melanoma	HLA-A*02:01	Uveal Melanoma	tebentafusp-tebn Sensitive: A1 - Approval tebentafusp-tebn Sensitive : A1	tebentafusp-tebn Sensitive: A1 - Approval tebentafusp-tebn Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	mosunetuzumab-axgb Sensitive: A1 - Approval mosunetuzumab-axgb Sensitive : A1	mosunetuzumab-axgb Sensitive: A1 - Approval mosunetuzumab-axgb Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	elranatamab-bcmm Sensitive: A1 - Approval elranatamab-bcmm Sensitive : A1	elranatamab-bcmm Sensitive: A1 - Approval elranatamab-bcmm Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	glofitamab-gxbm Sensitive: A1 - Approval glofitamab-gxbm Sensitive : A1	glofitamab-gxbm Sensitive: A1 - Approval glofitamab-gxbm Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	epcoritamab-bysp Sensitive: A1 - Approval epcoritamab-bysp Sensitive : A1	epcoritamab-bysp Sensitive: A1 - Approval epcoritamab-bysp Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	talquetamab-tgvs Sensitive: A1 - Approval talquetamab-tgvs Sensitive : A1	talquetamab-tgvs Sensitive: A1 - Approval talquetamab-tgvs Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	epcoritamab-bysp Sensitive: A1 - Approval epcoritamab-bysp Sensitive : A1	epcoritamab-bysp Sensitive: A1 - Approval epcoritamab-bysp Sensitive : A1
No biomarker	Mediastinal B Cell Lymphoma	No biomarker	Mediastinal B Cell Lymphoma	epcoritamab-bysp Sensitive: A1 - Approval epcoritamab-bysp Sensitive : A1	epcoritamab-bysp Sensitive: A1 - Approval epcoritamab-bysp Sensitive : A1
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	blinatumomab Sensitive: A2 - Guideline blinatumomab Sensitive : A2	blinatumomab Sensitive: A2 - Guideline blinatumomab Sensitive : A2
No biomarker	Acute Lymphocytic Leukemia	No biomarker	Acute Lymphocytic Leukemia	blinatumomab + inotuzumab ozogamicin Sensitive: A2 - Guideline blinatumomab + inotuzumab ozogamicin Sensitive : A2	blinatumomab + inotuzumab ozogamicin Sensitive: A2 - Guideline blinatumomab + inotuzumab ozogamicin Sensitive : A2
No biomarker	B Acute Lymphoblastic Leukemia	No biomarker	B Acute Lymphoblastic Leukemia	blinatumomab + inotuzumab ozogamicin Sensitive: A2 - Guideline blinatumomab + inotuzumab ozogamicin Sensitive : A2	blinatumomab + inotuzumab ozogamicin Sensitive: A2 - Guideline blinatumomab + inotuzumab ozogamicin Sensitive : A2
HLA-A*02:01	Uveal Melanoma	HLA-A*02:01	Uveal Melanoma	ipilimumab + tebentafusp-tebn Sensitive: A2 - Guideline ipilimumab + tebentafusp-tebn Sensitive : A2	ipilimumab + tebentafusp-tebn Sensitive: A2 - Guideline ipilimumab + tebentafusp-tebn Sensitive : A2
CD20 positive	B Acute Lymphoblastic Leukemia	CD20 positive	B Acute Lymphoblastic Leukemia	rituximab + blinatumomab Sensitive: A2 - Guideline rituximab + blinatumomab Sensitive : A2	rituximab + blinatumomab Sensitive: A2 - Guideline rituximab + blinatumomab Sensitive : A2
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	MK-4002 Sensitive: B - Late Trials MK-4002 Sensitive : B	MK-4002 Sensitive: B - Late Trials MK-4002 Sensitive : B
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	BI 764532 Sensitive: B - Late Trials BI 764532 Sensitive : B	BI 764532 Sensitive: B - Late Trials BI 764532 Sensitive : B
No biomarker	Neuroendocrine Tumor	No biomarker	Neuroendocrine Tumor	BI 764532 Sensitive: B - Late Trials BI 764532 Sensitive : B	BI 764532 Sensitive: B - Late Trials BI 764532 Sensitive : B
DLL3 expression	Neuroendocrine Tumor	DLL3 expression	Neuroendocrine Tumor	BI 764532 Sensitive: B - Late Trials BI 764532 Sensitive : B	BI 764532 Sensitive: B - Late Trials BI 764532 Sensitive : B
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	tarlatamab-dlle Sensitive: B - Late Trials tarlatamab-dlle Sensitive : B	tarlatamab-dlle Sensitive: B - Late Trials tarlatamab-dlle Sensitive : B
CD20 positive	Diffuse Large B Cell Lymphoma	CD20 positive	Diffuse Large B Cell Lymphoma	epcoritamab-bysp Sensitive: C2 – Inclusion Criteria epcoritamab-bysp Sensitive : C2	epcoritamab-bysp Sensitive: C2 – Inclusion Criteria epcoritamab-bysp Sensitive : C2
CD20 positive	Follicular Lymphoma	CD20 positive	Follicular Lymphoma	epcoritamab-bysp Sensitive: C2 – Inclusion Criteria epcoritamab-bysp Sensitive : C2	epcoritamab-bysp Sensitive: C2 – Inclusion Criteria epcoritamab-bysp Sensitive : C2
CLDN6 expression	Non Small Cell Lung Cancer	CLDN6 expression	Non Small Cell Lung Cancer	AMG 794 Sensitive: C2 – Inclusion Criteria AMG 794 Sensitive : C2	AMG 794 Sensitive: C2 – Inclusion Criteria AMG 794 Sensitive : C2
CLDN6 expression	Ovarian Cancer	CLDN6 expression	Ovarian Cancer	AMG 794 Sensitive: C2 – Inclusion Criteria AMG 794 Sensitive : C2	AMG 794 Sensitive: C2 – Inclusion Criteria AMG 794 Sensitive : C2
BCR-ABL1 fusion	Acute Lymphocytic Leukemia	BCR-ABL1 fusion	Acute Lymphocytic Leukemia	blinatumomab Sensitive: C2 – Inclusion Criteria blinatumomab Sensitive : C2	blinatumomab Sensitive: C2 – Inclusion Criteria blinatumomab Sensitive : C2
CLDN18.2 expression	Pancreatic Cancer	CLDN18.2 expression	Pancreatic Cancer	ASP2138 Sensitive: C2 – Inclusion Criteria ASP2138 Sensitive : C2	ASP2138 Sensitive: C2 – Inclusion Criteria ASP2138 Sensitive : C2
CLDN18.2 expression	Gastric Cancer	CLDN18.2 expression	Gastric Cancer	ASP2138 Sensitive: C2 – Inclusion Criteria ASP2138 Sensitive : C2	ASP2138 Sensitive: C2 – Inclusion Criteria ASP2138 Sensitive : C2
CD22 positive	B Acute Lymphoblastic Leukemia	CD22 positive	B Acute Lymphoblastic Leukemia	blinatumomab + inotuzumab ozogamicin Sensitive: C2 – Inclusion Criteria blinatumomab + inotuzumab ozogamicin Sensitive : C2	blinatumomab + inotuzumab ozogamicin Sensitive: C2 – Inclusion Criteria blinatumomab + inotuzumab ozogamicin Sensitive : C2

CD3 agonist

CD3 agonist

Associations(148)

Associations
(148)